Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Oral Supplementation of Lutein-in-extra-virgin-olive-oil Improved Retinal Function in Oxygen-Induced Retinopathy Mouse Model
Author Affiliations & Notes
  • Xiaoyuan YE
    Ophthalmology, The University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, China
  • Nicholas Siu Kay Fung
    Ophthalmology, The University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, China
  • Wai Ching Lam
    Ophthalmology, The University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, China
  • Amy Cy Lo
    Ophthalmology, The University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, China
  • Footnotes
    Commercial Relationships   Xiaoyuan YE None; Nicholas Siu Kay Fung None; Wai Ching Lam None; Amy Lo None
  • Footnotes
    Support  The Health and Medical Research Fund of Hong Kong (No. 09201116)
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 293. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Xiaoyuan YE, Nicholas Siu Kay Fung, Wai Ching Lam, Amy Cy Lo; Oral Supplementation of Lutein-in-extra-virgin-olive-oil Improved Retinal Function in Oxygen-Induced Retinopathy Mouse Model. Invest. Ophthalmol. Vis. Sci. 2024;65(7):293.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Retinopathy of prematurity (ROP) is a major cause of childhood blindness in preterm infants, attributed to oxidative stress. Lutein is a strong antioxidant with the potential to mitigate ROP. To enhance the bioavailability of lutein, extra virgin olive oil (EVOO) was used to dissolve lutein. Here, we explored the potential of oral supplementation of lutein-in-extra-virgin-olive-oil (LEVOO) as a non-invasive management for ROP using a mouse oxygen-induced retinopathy (OIR) model.

Methods : Neonatal C57BL/6J mice were exposed to 75% O2 from postanal day 7 (P7) to P12 followed by daily gavage of different volumes of water, olive oil (OO, for caloric control), or EVOO. Dosing volume was optimized by evaluation of retinal function and pathologic vasculature using electroretinography (ERG) and isolectin-stained retinal flat mounts, respectively on P17. Lutein was then dissolved in 4 mL/kg EVOO (best dosing volume) to attain the intended dosages of 0.4, 1.8, and 3.6 mg/kg (LEVOO). P12 mice after OIR received various dosages of LEVOO via oral gavage daily. On P17, retinal function was assessed with scotopic ERG. Data were analyzed with One-way ANOVA followed by Dunnett’s post hoc test.

Results : Mice subjected to OO or EVOO peroral administration displayed similar body weight and a- or b-wave amplitudes in ERG as well as comparable avascular and neovascular areas when compared with water-treated mice. After OIR, LEVOO-treated mice yielded a dose-responsive b-wave amplitude increase measured at various light intensities (0.01, 0.1, 1 and 3 cd.s/m2). Notably, mice treated with LEVOO at 3.6 mg/kg displayed significantly larger b-wave amplitudes (at 1 cd.s/m2) than those treated with EVOO (EVOO: 193.8 ± 20.4 μV, LEVOO 3.6 mg/kg: 304.8 ± 33.9 μV, n=3-6, p<0.05).

Conclusions : EVOO is a safe oral drug delivery vehicle in the OIR model. LEVOO-treated neonates exhibited improved retinal function, suggesting that LEVOO might rescue bipolar cells after OIR.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×